Could this Healthcare Stock really climb 689.47% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [New EV Lithium Player?]( company surges over 178% after recent acquisition in new Lithium epicenter! [See Report]( --------------------------------------------------------------- December 12, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Tiny Lithium Stock Surge!]( t miss out on this tiny stock poised to surge in a massive $183B market opportunity! [Get the Free Report]( --------------------------------------------------------------- [ESSA Pharma]( Symbol: [EPIX]( Recent Price: $5.35 Average Analyst Price Target: $18.33 (242.62%) Market Cap: $240.79M Last Year's EPS: -$0.16 Consensus EPS Forecast: -$0.2 Expected Earnings Date: Dec 14 2023 Recent Analyst Action: Joseph Catanzaro, analyst at Piper Sandler, reiterates coverage on [ESSA Pharma (EPIX)]( in the Healthcare sector with a Buy rating and a price target of $15 (1 month ago). [TipRanks.com]( also reports that [ESSA Pharma]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.33 . The target pricing ranges from a high forecast of $23 down to a low forecast of $15. [ESSA Pharma (EPIX)](’s last closing price was $5.35 which would put the average price target at 242.62% upside. Here are 3rd party ratings for [EPIX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [GPT-4 vs. X.AI: The Race of the New AI Giants]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- [Veru]( Symbol: [VERU]( Recent Price: $0.86 Average Analyst Price Target: $6.25 (131.83%) Market Cap: $105.63M Last Year's EPS: -$0.44 Consensus EPS Forecast: -$0.2 Expected Earnings Date: Dec 14 2023 Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on [Veru (VERU)]( in the Healthcare sector with a Buy rating and a price target of $2 (2 months ago). [TipRanks.com]( also reports that [Veru]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.25 . The target pricing ranges from a high forecast of $7 down to a low forecast of $1. [Veru (VERU)](’s last closing price was $0.86 which would put the average price target at 131.83% upside. Here are 3rd party ratings for [VERU](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 43% (143 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [ImmunoPrecise Antibodies]( Symbol: [IPA]( Recent Price: $1.14 Average Analyst Price Target: $8.00 (689.47%) Market Cap: $28.31M Last Year's EPS: -$0.15 Consensus EPS Forecast: -$0.17 Expected Earnings Date: Dec 14 2023 Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [ImmunoPrecise Antibodies (IPA)]( in the Healthcare sector with a Buy rating and a price target of $9 (2 months ago). [TipRanks.com]( also reports that [ImmunoPrecise Antibodies]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00 . The target pricing ranges from a high forecast of $9 down to a low forecast of $7. [ImmunoPrecise Antibodies (IPA)](’s last closing price was $1.14 which would put the average price target at 689.47% upside. Here are 3rd party ratings for [IPA](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 20% (51 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [cbdMD]( Symbol: [YCBD]( Recent Price: $0.73 Average Analyst Price Target: $3.00 (310.90%) Market Cap: $2.14M Last Year's EPS: -$1.74 Consensus EPS Forecast: -$0.76 Expected Earnings Date: Dec 14 2023 Recent Analyst Action: Anthony Vendetti, analyst at Maxim Group, reiterates coverage on [cbdMD (YCBD)]( in the Healthcare sector with a Buy rating and a price target of $3 (2 months ago). [TipRanks.com]( also reports that [cbdMD]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $3.00 . The target pricing ranges from a high forecast of $3 down to a low forecast of $3. [cbdMD (YCBD)](’s last closing price was $0.73 which would put the average price target at 310.90% upside. Here are 3rd party ratings for [YCBD](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"]( The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. [Get the name of the stock here ]( --------------------------------------------------------------- [Darden]( Symbol: [DRI]( Recent Price: $161.20 Average Analyst Price Target: $172.20 (4.15%) Market Cap: $19.12B Last Year's EPS: $2.58 Consensus EPS Forecast: $1.74 Expected Earnings Date: Dec 15 2023 Recent Analyst Action: Andrew Charles, analyst at TD Cowen, reiterates coverage on [Darden (DRI)]( in the Consumer Cyclical sector with a Buy rating and a price target of $175 (23 hours ago). [TipRanks.com]( also reports that [Darden]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $172.20 . The target pricing ranges from a high forecast of $187 down to a low forecast of $159. [Darden (DRI)](’s last closing price was $161.20 which would put the average price target at 4.15% upside. Here are 3rd party ratings for [DRI](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 27% (67 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The New Epicenter for Lithium!]( company makes big acquisition in new epicenter of Lithium supply for EV's! [Get Symbol]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software